BREAST CANCER

乳腺癌

• 批准号: 8436433
• 负责人: William L. Carroll
• 金额: $ 2.34万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-03-01 至 2018-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8436433
• 关键词: Address; Advanced Development; Angiogenesis Inhibitors; Area; Basic Science; Biological Markers; Biology; Breast; Breast Cancer Education; Breast Cancer Epidemiology; Breast Cancer Treatment; Cancer Biology; Cancer Burden; Cancer Center Support Grant; Cancer Control; Cancer Etiology; Cancer Patient; Cancer Research Project; Cancer Survivor; Caring; Cessation of life; Clinic; Clinical; Clinical Investigator; Clinical Research; Clinical Trials; Collaborations; Commit; Communities; Development; Developmental Therapeutics Program; Diagnosis; Discipline; Early Diagnosis; Economic Factors; Environmental Risk Factor; Epidemiology; Extracellular Matrix; Faculty; Funding; Future; Genetic Determinism; Goals; Grant; Health Services Accessibility; Hormonal; Hospitals; Hour; Human Genetics; Human Microbiome; Immunity; Individual; Institutes; Instruction; Ionizing radiation; Journals; Laboratories; Malignant Neoplasms; Medical Oncology; Medicine; Metabolic; Methods; Minority; Mission; Modification; Molecular; Molecular Genetics; Neoplasm Metastasis; Neoplastic Cell Transformation; New York; Obesity; Paper; Pathogenesis; Pathology; Pathway interactions; Patients; Physics; Population; Population Heterogeneity; Prevention; Psychiatry; Public Hospitals; Publications; Publishing; Quality of life; Radiation Oncology; Radiobiology; Radiology Specialty; Recording of previous events; Recruitment Activity; Recurrence; Regulation; Reproductive History; Research; Research Institute; Research Personnel; Research Project Grants; Risk Factors; Role; School Nursing; Scientist; Screening for cancer; Services; Signal Transduction; Surgical Oncology; Survivors; Systems Biology; Therapeutic; Time; Tobacco use; Translating; Translational Research; Translations; Tumor Immunity; Underserved Population; United States; Woman; Work; angiogenesis; anticancer research; base; cancer invasiveness; cancer prevention; cancer risk; cancer stem cell; cancer therapy; evidence base; forging; immunological intervention; improved; innovation; insight; malignant breast neoplasm; medically underserved; meetings; member; mortality; multidisciplinary; novel; outreach; population based; programs; screening; symposium; tumor; tumor immunology; tumor microenvironment; tumor progression

PROJECT SUMMARY (See instructions); The Epidemiology & Cancer Control Program is composed of 34 investigators (30 Full and 4 Associate members) from 12 Departments. The overall mission of the Program is to reduce the risk of cancer occurrence and death and to enhance the quality of life of cancer survivors. To fulfill this mission, it has 4 major scientific objectives: 1) To identify environmental and genetic determinants of cancer to improve means of cancer prevention, focusing specifically on understanding the role of environmental factors in cancer etiology, determining the metabolic and reproductive factors in cancer etiology, understanding the role of human genetics in cancer etiology and progression, and identifying cancer risks associated with the human microbiome; 2) To reduce cancer burden by risk factor modification, with a specific focus on obesity control and tobacco use reduction; 3) To reduce cancer burden by early detection of cancer, with a specific focus on the application of methods to increase screening participation by underserved populations and the development of novel early detection biomarkers; and 4) To address cancer-related burden in patients and survivors, with a particular emphasis on meeting the needs of the underserved. The research focus areas are interdisciplinary, including population, laboratory and clinical scientists from ECC and other NYU Cancer Institute Research Programs. Drs. Richard Hayes and Brian Schmidt are the Co-Leaders for this Program. This is a new Program that currently has $16,940,943 on funding. Publications for the period total 216, of which 17.6% are intra-programmatic, 11.1% are inter-programmatic, and 8.8% are both intra- and interprogrammatic collaborations. RELEVANCE (See instructions): The Epidemiology and Cancer Control Program undertakes epidemiological research on cancer and evaluates cancer prevention and outreach efforts, thus contributing to the evidence-base for effective cancer burden reduction programs in the diverse New York regional population and more broadly. PROJECT SUMMARY (See instructions): The Breast Cancer Program is composed of 38 investigators (32 Full and 6 Associate members) from 17 Departments. The Program aims to integrate so do-cultural disparities and population-based research with laboratory-based basic, translational and clinical research programs that can change the state of breast cancer mortality through a synergistic understanding of breast cancer and innovative approaches in treatment. To do so, they have developed the following Specific Aims: 1) Understand the so do-cultural and economic factors that impede diagnosis and care and contribute to disparities in treatment and survival; 2) Understand the immunological, micro-environmental, genetic and molecular mechanisms that contribute to the development, invasion, recurrence and metastasis of breast cancer; 3) Translate scientific findings to breast cancer development and progression into innovative therapeutics and therapeutic approaches to benefit patients by improving diagnosis and treatment; and 4) Advance the development of clinicians and research scientists working collaboratively to establish novel basic, translational and clinical research areas. To address these aims, six major areas are being developed: 1) Hormonal signaling; 2) Invasiveness, metastasis and angiogenesis; 3) Immunity/immunological intervention and association with breast cancer; 4) Epidemiology; 5) Radiobiology and physics research in breast cancer; and 6) Socio-cultural and community based research and programs. Drs. Silvia Formenti and Robert Schneider are the Co-Leaders for this Program. Total funding increased from $9,789,777 to $11,595,777 since the last competitive application. Membership has decreased from 44 to 38. Publications for the period total 275, of which 16.7% are intraprogrammatic, 16% are inter-programmatic, and 8.7% are both intra- and inter-programmatic collaborations.

项目摘要（请参阅说明）；流行病学和癌症控制计划由来自12个部门的34名调查人员（30名和4名员工）组成。该计划的总体任务是减少癌症发生和死亡的风险，并提高癌症幸存者的生活质量。为了实现这一任务，它具有4个主要科学目标：1）确定癌症的环境和遗传决定因素以改善预防癌症的手段，专门研究环境因素在癌症病因学中的作用，确定癌症病因的代谢和生殖因素在癌症病因学中的作用，了解人类遗传学在癌症病因学和人类癌症中的作用，并确定与人类癌症的风险相关。 2）通过改变危险因素来减轻癌症负担，特别关注肥胖控制和减少烟草的使用； 3）通过早期发现癌症来减轻癌症负担，特别着眼于应用方法来增加服务不足的人群的筛查参与以及新型早期检测生物标志物的发展； 4）解决患者和幸存者的癌症相关负担，特别是满足服务不足的需求。研究重点领域是跨学科的，包括来自ECC和其他NYU癌症研究所研究计划的人口，实验室和临床科学家。博士。理查德·海斯（Richard Hayes）和布莱恩·施密特（Brian Schmidt）是该计划的共同领导者。这是一个新计划，目前拥有16,940,943美元的资金。总计216期的出版物，其中17.6％为概括性内部，有11.1％是程序间的，而8.8％的出版物均为内部和分解合作合作。相关性（请参阅说明）：流行病学和癌症控制计划进行了有关癌症的流行病学研究，并评估了癌症预防和外展工作，从而有助于循证纽约地区人口有效减少癌症负担计划的证据。项目摘要（请参阅说明）：乳腺癌计划由来自17个部门的38位调查人员（32名完整和6名副成员）组成。该计划旨在将基于文化的差异和基于人群的研究与基于实验室的基础，翻译和临床研究计划整合，这些计划可以通过对乳腺癌的协同理解和治疗中的创新方法来改变乳腺癌死亡的状态。为此，他们开发了以下具体目的：1）了解阻碍诊断和护理的SO文化和经济因素，并导致治疗和生存的差异； 2）了解有助于乳腺癌的发育，侵袭，复发和转移的免疫，微环境，遗传和分子机制； 3）将科学发现转化为乳腺癌的发展和进展，转化为创新的治疗剂和治疗方法，以改善诊断和治疗来使患者受益； 4）促进临床医生和研究科学家的发展，以建立新颖的基本，转化和临床研究领域。为了解决这些目标，正在开发六个主要领域：1）激素信号传导； 2）侵袭性，转移和血管生成； 3）免疫/免疫干预措施以及与乳腺癌的关联； 4）流行病学； 5）乳腺癌的放射生物学和物理研究； 6）基于社会文化和社区的研究和计划。博士。 Silvia Formenti和Robert Schneider是该计划的共同领导者。自上次竞争申请以来，总资金从9,789,777美元增加到11,595,777美元。成员资格已从44个下降到38个。总计275期的出版物，其中16.7％是磁内部的，16％是截面的，并且8.7％均为内部和程序间合作。